Darren E. Insko

A small molecule–kinase interaction map for clinical kinase inhibitors

L. Wodicka, D. Lockhart, P. Zarrinkar, 2005, Nature Biotechnology.

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

William Pao, Harold Varmus, Daniel K Treiber, 2005, Proceedings of the National Academy of Sciences of the United States of America.

CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity

Raffaella Faraoni, Darren E. Insko, P. Dobrzanski, 2012, Molecular Cancer Therapeutics.

Preclinical Development CEP-32496 : A Novel Orally Active BRAFV 600 E Inhibitor with Selective Cellular and In Vivo Antitumor Activity

Raffaella Faraoni, Darren E. Insko, P. Dobrzanski, 2012 .

Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3

P. Zarrinkar, Darren E. Insko, M. Levis, 2008 .

Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors.

P. Zarrinkar, Darren E. Insko, R. Armstrong, 2015, Bioorganic & medicinal chemistry letters.

Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.

A. Ghose, Brian T. Campbell, Raffaella Faraoni, 2012, Journal of medicinal chemistry.

Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.

A. Ghose, Brian T. Campbell, Raffaella Faraoni, 2012, Journal of medicinal chemistry.